1,2-distearoyllecithin has been researched along with camptothecin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burke, TG; Gao, X | 1 |
| Burke, TG; Mishra, AK; Wall, ME; Wani, MC | 1 |
| Cabral-Lilly, D; Cafiso, DS; Cho, C; Dicko, A; Ellena, JF; Frazier, AA; Hinderliter, A; Liboiron, BD; Mayer, LD; Tardi, PG; Weber, T; Xie, X | 1 |
| Atyabi, F; Dinarvand, R; Esmaeili, F; Farkhondehfai, A | 1 |
| Anantha, M; Bally, M; Patankar, N; Ramsay, E; Waterhouse, D | 1 |
| Li, P; Lin, Y; Ran, H; Ren, J; Tan, J; Wang, Z; Zhang, Q; Zheng, Y | 1 |
| Anderson, BD; Modi, S; Xiang, TX | 1 |
| Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M | 1 |
8 other study(ies) available for 1,2-distearoyllecithin and camptothecin
| Article | Year |
|---|---|
Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine.
Topics: Antineoplastic Agents; Buffers; Camptothecin; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Humans; Hydrogen-Ion Concentration; Lactones; Liposomes; Phosphatidylcholines; Topotecan | 1994 |
Lipid bilayer partitioning and stability of camptothecin drugs.
Topics: Binding Sites; Camptothecin; Dimyristoylphosphatidylcholine; Drug Stability; Fluorescence Polarization; Hydrogen-Ion Concentration; Kinetics; Lipid Bilayers; Phosphatidylcholines; Phosphatidylglycerols; Spectrometry, Fluorescence; Spectrophotometry; Structure-Activity Relationship | 1993 |
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Calorimetry; Camptothecin; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Cholesterol; Copper; Drug Carriers; Drug Compounding; Excipients; Floxuridine; Gluconates; Irinotecan; Liposomes; Magnetic Resonance Spectroscopy; Microscopy, Electron, Transmission; Phosphatidylcholines; Phosphatidylglycerols; Solubility; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2008 |
Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry, Pharmaceutical; Drug Stability; Female; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tissue Distribution | 2009 |
The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.
Topics: Animals; Antineoplastic Agents; Calcimycin; Camptothecin; Cell Membrane Permeability; Chemistry, Pharmaceutical; Cholesterol; Chromatography, High Pressure Liquid; Copper; Female; Ionophores; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Phosphatidylcholines | 2011 |
Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Male; Mice; Microbubbles; Neoplasms; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Sonication; Tumor Burden | 2012 |
Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions.
Topics: Camptothecin; Drug Compounding; Hydrogen-Ion Concentration; Liposomes; Models, Theoretical; Organosilicon Compounds; Permeability; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Solubility; Solutions | 2012 |
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholesterol; Colon; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Female; Fluorouracil; Intestine, Small; Irinotecan; Liposomes; Nanoparticles; Phosphatidylcholines; Rats, Sprague-Dawley | 2014 |